{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:06:21Z","timestamp":1770969981535,"version":"3.50.1"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[1999,11,1]],"date-time":"1999-11-01T00:00:00Z","timestamp":941414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1999,11,1]],"date-time":"1999-11-01T00:00:00Z","timestamp":941414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[1999,11]]},"DOI":"10.1136\/ard.58.2008.i73","type":"journal-article","created":{"date-parts":[[2008,12,6]],"date-time":"2008-12-06T00:32:33Z","timestamp":1228523553000},"page":"I73-I81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"S1","title":["PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases"],"prefix":"10.1016","volume":"58","author":[{"suffix":"III","given":"Carl K","family":"Edwards","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.58.2008.i73_bib1","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1073\/pnas.72.9.3666","article-title":"An endotoxin-induced serum factor that causes necrosis of tumors.","volume":"72","author":"Carswell","year":"1975","journal-title":"Proc Natl Acad SciUSA"},{"key":"10.1136\/ard.58.2008.i73_bib2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0140-6736(95)90055-1","article-title":"TNF and Mae West or: death from too much of a good thing.","volume":"345","author":"Tracey","year":"1995","journal-title":"Lancet [commentary]."},{"key":"10.1136\/ard.58.2008.i73_bib3","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1056\/NEJM199606273342607","article-title":"The tumor necrosis factor ligand and receptor families.","volume":"334","author":"Bazzoni","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.58.2008.i73_bib4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF00832003","article-title":"Role of pro-inflammatory cytokines in rheumatoid arthritis.","volume":"20","author":"Brennan","year":"1998","journal-title":"Springer Semin Immunopathol"},{"key":"10.1136\/ard.58.2008.i73_bib5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1056\/NEJM199707173370310","article-title":"Anticytokine therapy in rheumatoid arthritis.","volume":"337","author":"Firestein","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.58.2008.i73_bib6","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1146\/annurev.iy.07.040189.003205","article-title":"The biology of cachectin\/TNF\u2014a primary mediator of the host response.","volume":"7","author":"Beutler","year":"1989","journal-title":"Annu Rev Immunol"},{"key":"10.1136\/ard.58.2008.i73_bib7","series-title":"Xenobiotic induced inflammation: roles of cytokines and growth factors.","first-page":"97","article-title":"Role of tumor necrosis factor-alpha (TNF-alpha) in acute and chronic inflammatory responses: novel therapeutic approaches.","author":"Edwards","year":"1994"},{"key":"10.1136\/ard.58.2008.i73_bib8","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1084\/jem.180.6.2173","article-title":"Protective effect of 55-Kd but not 75-Kd soluble tumor-necrosis-factor receptor immunoglobulin-G fusion proteins in an animal-model of Gram-negative sepsis.","volume":"180","author":"Evans","year":"1994","journal-title":"J Exp Med"},{"key":"10.1136\/ard.58.2008.i73_bib9","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJM199606273342603","article-title":"Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein.","volume":"334","author":"Fisher Jr","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.58.2008.i73_bib10","first-page":"16","article-title":"The role of tumor necrosis factor in health and disease.","volume":"26","author":"Beutler","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.58.2008.i73_bib11","first-page":"297","article-title":"Anti-tumor necrosis factor alpha therapy of rheumatoid arthritis.","volume":"8","author":"Feldmann","year":"1997","journal-title":"Eur Cytokine Netw"},{"key":"10.1136\/ard.58.2008.i73_bib12","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1126\/science.8171316","article-title":"Unraveling function in the TNF ligand and receptor families.","volume":"264","author":"Beutler","year":"1994","journal-title":"Science"},{"key":"10.1136\/ard.58.2008.i73_bib13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0092-8674(93)90132-A","article-title":"Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation.","volume":"73","author":"Banner","year":"1993","journal-title":"Cell"},{"key":"10.1136\/ard.58.2008.i73_bib14","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/0092-8674(93)90326-L","article-title":"Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family.","volume":"75","author":"Suda","year":"1993","journal-title":"Cell"},{"key":"10.1136\/ard.58.2008.i73_bib15","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1073\/pnas.95.2.570","article-title":"The type I receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor.","volume":"95","author":"Grell","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1136\/ard.58.2008.i73_bib16","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/emboj\/18.8.2119","article-title":"A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in \u2018reverse signalling\u2019.","volume":"18","author":"Watts","year":"1999","journal-title":"EMBO J"},{"key":"10.1136\/ard.58.2008.i73_bib17","first-page":"382","article-title":"Soluble tumor necrosis factor receptors in arthritis. J.","volume":"22","author":"Cope","year":"1995","journal-title":"Rheumatol."},{"key":"10.1136\/ard.58.2008.i73_bib18","doi-asserted-by":"crossref","first-page":"8331","DOI":"10.1073\/pnas.87.21.8331","article-title":"A second tumor necrosis factor gene product can yield a naturally occuring tumor necrosis factor inhibitor.","volume":"87","author":"Kohno","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1136\/ard.58.2008.i73_bib19","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1073\/pnas.89.11.4845","article-title":"Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo.","volume":"89","author":"Van Zee","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1136\/ard.58.2008.i73_bib20","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1177\/019262339902700125","article-title":"Animal models of arthritis: relevance to human disease.","volume":"27","author":"Bendele","year":"1999","journal-title":"Toxicol Pathol"},{"key":"10.1136\/ard.58.2008.i73_bib21","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s000110050486","article-title":"Combination benefit of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) and dexamethasone or indomethacin in adjuvant arthritic rats.","volume":"48","author":"Bendele","year":"1999","journal-title":"Inflamm Res"},{"key":"10.1136\/ard.58.2008.i73_bib22","unstructured":"Bendele AM, McComb J, Gould T, et al. Effects of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) alone ands in combination with methotrexate in adjuvant arthritic rats. Clin Exp Rheumatol (in press)."},{"key":"10.1136\/ard.58.2008.i73_bib23","first-page":"1347","article-title":"Anti-arthritic activity of soluble TNF receptor forms in adjuvant arthritis: correlation of plasma levels with efficacy.","volume":"26","author":"McComb","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.58.2008.i73_bib24","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1136\/ard.58.2008.i73_bib25","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/art.1780361206","article-title":"Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.","volume":"36","author":"Elliott","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.58.2008.i73_bib26","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0140-6736(94)90632-7","article-title":"Repeated therapy with monoclonal-antibody to tumor necrosis factor alpha (cA2) in patients with rheumatoid arthritis.","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1136\/ard.58.2008.i73_bib27","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1152\/jappl.1998.84.4.1119","article-title":"Pharmacokinetics, immunogenicity and efficacy of dimeric TNFR binding proteins in healthy and bacteremic baboon.","volume":"84","author":"Solorzano","year":"1998","journal-title":"J Appl Physiol"},{"key":"10.1136\/ard.58.2008.i73_bib28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/1529-0131(199801)41:1<139::AID-ART17>3.0.CO;2-T","article-title":"Soluble TNF receptor prevents arthritis and pneumonitis in motheaten mice.","volume":"41","author":"Yang","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.58.2008.i73_bib29","first-page":"s279","article-title":"Inhibition of tumor necrosis factor (TNF) is effective alone or in combination with inhibition of interleukin-1 (IL-1) in reducing joint swelling in rodent bacterial cell wall-induced arthritis.","volume":"37","author":"Russell","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.58.2008.i73_bib30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1006\/jsre.1995.1147","article-title":"PEG-BP-30 monotherapy attenuates the cytokine-mediated inflammatory cascade in baboon Escherichia coli septic shock.","volume":"59","author":"Espat","year":"1995","journal-title":"JSurg Res"},{"key":"10.1136\/ard.58.2008.i73_bib31","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4049\/jimmunol.158.1.414","article-title":"Involvement of 26-kDa cell associated TNF\u03b1 in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor.","volume":"158","author":"Solorzano","year":"1997","journal-title":"J Immunol"},{"key":"10.1136\/ard.58.2008.i73_bib32","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1378\/chest.110.4.992","article-title":"The clinical relevance of circulating tumor necrosis factor-alpha in acute decompensated chronic heart failure without cachexia.","volume":"110","author":"Milani","year":"1996","journal-title":"Chest"},{"key":"10.1136\/ard.58.2008.i73_bib33","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1359-6446(97)01052-0","article-title":"Therapeutic potential of TNF-\u03b1 inhibitors old and new.","volume":"2","author":"Marriott","year":"1997","journal-title":"Drug Development Today"},{"key":"10.1136\/ard.58.2008.i73_bib34","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.4049\/jimmunol.156.6.2221","article-title":"Protection against lethal Escherichia bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45\u20132081.","volume":"156","author":"Van Zee","year":"1996","journal-title":"J Immunol"},{"key":"10.1136\/ard.58.2008.i73_bib35","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJM199606273342603","article-title":"Treatment of septic shock with the tumor necrosis factor receptor:Fc.","volume":"334","author":"Fisher","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.58.2008.i73_bib36","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jama.1997.03540430043031","article-title":"p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial.","volume":"277","author":"Abraham","year":"1997","journal-title":"JAMA"},{"key":"10.1136\/ard.58.2008.i73_bib37","first-page":"7","article-title":"Inhibitors of tumor necrosis factor for rheumatoid arthritis.","volume":"26","author":"Moreland","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.58.2008.i73_bib38","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1084\/jem.175.2.323","article-title":"Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors.","volume":"175","author":"Aderka","year":"1992","journal-title":"J Exp Med"},{"key":"10.1136\/ard.58.2008.i73_bib39","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.4049\/jimmunol.151.3.1548","article-title":"Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists.","volume":"151","author":"Mohler","year":"1993","journal-title":"J Immunol"},{"key":"10.1136\/ard.58.2008.i73_bib40","doi-asserted-by":"crossref","first-page":"18542","DOI":"10.1016\/S0021-9258(17)46661-0","article-title":"Ligand passing: the 75-Kd tumor necrosis factor (TNF) receptor recrutis TNF for signaling by the 55 Kd TNF receptor.","volume":"268","author":"Tartaglia","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1136\/ard.58.2008.i73_bib41","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/archsurg.133.5.558","article-title":"Revisiting the role of tumor necrosis factor alpha and the response to surgical injury and inflammation.","volume":"133","author":"Ksontini","year":"1999","journal-title":"Arch Surg"},{"key":"10.1136\/ard.58.2008.i73_bib42","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/nm1197-1193","article-title":"TNF inhibition and sepsis-sounding a cautionary note.","volume":"3","author":"Grau","year":"1997","journal-title":"Nat Med"},{"key":"10.1136\/ard.58.2008.i73_bib43","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00002281-199905000-00005","article-title":"Biologic agents in the treatment of inflammatory rheumatic diseases.","volume":"11","author":"Lorenz","year":"1999","journal-title":"Curr Opin Rheumatol"},{"key":"10.1136\/ard.58.2008.i73_bib44","first-page":"563","article-title":"Interleukin-1, tumor necrosis factor and their specific inhibitors.","volume":"5","author":"Dayer","year":"1994","journal-title":"European Cytokine Review"},{"key":"10.1136\/ard.58.2008.i73_bib45","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/art.1780330302","article-title":"Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.","volume":"33","author":"Arend","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.58.2008.i73_bib46","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/art.1780380202","article-title":"Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis.","volume":"38","author":"Arend","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.58.2008.i73_bib47","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0952-7915(98)80087-3","article-title":"Regulation of autoimmunity by proinflammatory cytokines.","volume":"10","author":"Cope","year":"1998","journal-title":"Curr Opin Immunol"},{"key":"10.1136\/ard.58.2008.i73_bib48","first-page":"480","article-title":"Cytokine production in the rheumatoid joint: implications for treatment.","volume":"49","author":"Feldmann","year":"1990","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.58.2008.i73_bib49","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.4049\/jimmunol.159.6.2867","article-title":"DBA\/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis.","volume":"159","author":"Butler","year":"1997","journal-title":"J Immunol"},{"key":"10.1136\/ard.58.2008.i73_bib50","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1365-3083.1999.00458.x","article-title":"Distribution of TNF-alpha, TNF-R55 and TNF-R75 in the rheumatoid synovial membrane: TNF receptors are localized preferentially in the lining layer; TNF-alpha is distributed mainly in the vicinity of TNF receptors in the deeper layers.","volume":"49","author":"Alsalameh","year":"1999","journal-title":"Scand J Immunol"},{"key":"10.1136\/ard.58.2008.i73_bib51","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1006\/cyto.1995.1004","article-title":"Multifunctional regulation of the biological effects of TNF-alpha by the soluble type I and type II TNF receptors.","volume":"7","author":"Hale","year":"1995","journal-title":"Cytokine"},{"key":"10.1136\/ard.58.2008.i73_bib52","first-page":"1510","article-title":"Concentration and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid.","volume":"24","author":"Desgeorges","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.58.2008.i73_bib53","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-3083.1995.tb03639.x","article-title":"TNF inhibitors are produced spontaneously by rheumatoid and osteoarthritic synovial joint cell cultures: evidence of feedback control of TNF action.","volume":"42","author":"Brennan","year":"1995","journal-title":"Scand J Immunol"},{"key":"10.1136\/ard.58.2008.i73_bib54","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.58.2008.i73_bib55","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/1529-0131(199809)41:9<1564::AID-ART6>3.0.CO;2-M","article-title":"Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvements in core set measures, rather than twenty percent?","volume":"41","author":"Felson","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.58.2008.i73_bib56","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1159\/000237393","article-title":"What is the mechanism of action of anti-tumour necrosis factor-alpha antibody in rheumatoid arthritis?","volume":"111","author":"Feldmann","year":"1996","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1136\/ard.58.2008.i73_bib57","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0092-8674(00)81109-5","article-title":"Rheumatoid arthritis.","volume":"85","author":"Feldmann","year":"1996","journal-title":"Cell"},{"key":"10.1136\/ard.58.2008.i73_bib58","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1699-0463.1997.tb00567.x","article-title":"TNF blockade in rheumatoid arthritis: implications for therapy and pathogenesis.","volume":"105","author":"Maini","year":"1997","journal-title":"APMIS"},{"key":"10.1136\/ard.58.2008.i73_bib59","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1146\/annurev.immunol.14.1.397","article-title":"Role of cytokines in rheumatoid arthritis.","volume":"14","author":"Feldmann","year":"1996","journal-title":"Annu Rev Immunol"},{"key":"10.1136\/ard.58.2008.i73_bib60","series-title":"Novel therapeutic agents for the treatment of autoimmune diseases.","first-page":"121","article-title":"Engineered human anti-tumor necrosis factor-alpha (TNF\u03b1) antibody, CDP571, in rheumatoid arthritis.","author":"Choy","year":"1997"},{"key":"10.1136\/ard.58.2008.i73_bib61","first-page":"621","article-title":"Clinical trials on biologics in rheumatoid arthritis.","volume":"36","author":"Sander","year":"1998","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1136\/ard.58.2008.i73_bib62","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","article-title":"Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.","volume":"337","author":"Moreland","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.58.2008.i73_bib63","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial.","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.58.2008.i73_bib64","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0065-2776(08)60891-3","article-title":"Anti- tumor necrosis factor-alpha therapy of rheumatoid arthritis.","volume":"64","author":"Feldmann","year":"1996","journal-title":"Adv Immunol"},{"key":"10.1136\/ard.58.2008.i73_bib65","unstructured":"Moreland LW, McCabe D, Caldwell JR, et al. Recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer (TNFbp Dimer) in patients with active refractory rheumatoid arthritis. J Rheumatol (in press)."},{"key":"10.1136\/ard.58.2008.i73_bib66","first-page":"S58","article-title":"Assessment of the major antigenic epitopes of the recombinant human soluble p55 TNF type I receptor: design of a novel monomeric non-immunogenic analog, sTNF-RI.","volume":"41","author":"Edwards","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.58.2008.i73_bib67","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4049\/jimmunol.151.1.389","article-title":"Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge.","volume":"151","author":"Parmely","year":"1993","journal-title":"J Immunol"},{"key":"10.1136\/ard.58.2008.i73_bib68","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1172\/JCI118045","article-title":"The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor.","volume":"96","author":"Burger","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1136\/ard.58.2008.i73_bib69","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/art.1780281213","article-title":"Reactivation of streptococcal cell wall-induced arthritis by homologous cell wall polymers.","volume":"28","author":"Esser","year":"1985","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.58.2008.i73_bib70","first-page":"S284","article-title":"Efficacy of tumor necrosis factor binding protein (TNF-bp) in the streptococcal cell wall-induced reactivation model of arthritis.","volume":"39","author":"Evans","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.58.2008.i73_bib71","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/1529-0131(199904)42:3<498::AID-ANR15>3.0.CO;2-A","article-title":"Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis.","volume":"42","author":"Bendele","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.58.2008.i73_bib72","first-page":"S58","article-title":"A genetically modified tumor necrosis factor receptor I (sTNF-RI) that does not elicit antibody response in primates.","volume":"41","author":"Martin","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.58.2008.i73_bib73","unstructured":"Martin SW, Sommers JS, Macri MJ, et al. The Pharmacokinetics of subcutaneous injections of PEGylated recombinant methiopnyl human soluble tumor necrosis factor-type I receptor (PEG sTNF-RI) in subjects with active rheumatoid arthritis. Arthritis Rheum (in press)."},{"key":"10.1136\/ard.58.2008.i73_bib74","unstructured":"Caldwell JR, Davis MW, Jelaca-Maxwell K, et al. A phase 1 study of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI [p55]) in subjects with rheumatoid arthritis (RA). Arthritis Rheum (in press)."}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724499159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724499159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.58.2008.i73","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T08:24:10Z","timestamp":1737361450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724499159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,11]]},"references-count":74,"alternative-id":["S0003496724499159"],"URL":"https:\/\/doi.org\/10.1136\/ard.58.2008.i73","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[1999,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.58.2008.i73","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1999 Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}